Kite Pharma gets exclusive rights to immunotherapies and technology from Alpine Immune Sciences
Executive Summary
Alpine Immune Sciences Inc. granted Kite Pharma Inc. exclusive global rights to its transmembrane immunomodulatory protein (TIP) technology and two associated cancer immunotherapy programs, which Kite will further develop into chimeric antigen receptor (CAR) and T-cell receptor (TCR) drug candidates.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice